Related Experiment Video
Updated: May 17, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
MDR1 polymorphisms associated with risk and survival in diffuse large B-cell lymphoma
Li-Li Hu1, Bingyun Yu, Jine Yang
1Key Laboratory of Gene Engineering of the Ministry of Education, School of Life Sciences, Sun Yat-Sen University, P. R. China.
Leukemia & Lymphoma
|October 24, 2012
Summary
Genetic variations in the MDR1 gene are linked to diffuse large B-cell lymphoma (DLBCL) risk and patient survival. Specific MDR1 single nucleotide polymorphisms (SNPs) may influence DLBCL development and prognosis.
Area of Science:
- Pharmacogenomics
- Oncology
- Molecular Biology
Background:
- The MDR1 gene encodes an ATP-dependent efflux transporter crucial for xenobiotic protection.
- Five single nucleotide polymorphisms (SNPs) in the MDR1 gene were previously identified.
- Understanding the biological significance of MDR1 SNPs is important for disease risk and prognosis.
Purpose of the Study:
- To investigate the association between MDR1 gene polymorphisms and the risk of diffuse large B-cell lymphoma (DLBCL).
- To evaluate the impact of MDR1 SNPs on the survival rates of DLBCL patients.
- To identify potential prognostic factors among MDR1 polymorphisms in DLBCL.
Main Methods:
- Genotyping of five MDR1 SNPs (T-2410C, T-129C, C1236T, G2677T/A, C3435T) in 135 DLBCL patients and 376 controls.
- Statistical analysis, including p-value assessment and Bonferroni correction.
- Multivariate Cox regression analysis to determine independent prognostic factors for overall survival (OS).
Main Results:
- The MDR1 T-129C polymorphism (TC genotype) was associated with an increased risk of DLBCL (p=0.040), particularly in older patients (>50 years, p=0.011).
- MDR1 2677TT genotype correlated with worse survival rates compared to MDR1 2677G/A alleles (p=0.036).
- MDR1 G2677T/A polymorphism was identified as an independent prognostic factor for OS, with a combined effect with C3435T on DLBCL patient survival.
Conclusions:
- MDR1 T-129C, G2677T/A, and C3435T polymorphisms are associated with DLBCL risk and patient survival.
- While preliminary, these findings suggest MDR1 SNPs as potential biomarkers for DLBCL.
- Larger studies with extended follow-up are recommended to validate these associations.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...